MedTrace Logo

The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury

NCT06804291 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-02-03

No results posted yet for this study

Summary

The goal of this clinical trial was to determine if and how the biomarkers neurofilament light (NfL), brain lipid binding protein (BLBP), and amyloid precursor protein (APP) accumulated over 72 hours in venous blood following running, cycling, or playing rugby as compared to a non-exercising control group. Participants in this study were recreationally active and healthy males and females 18 - 49 years of age. The main questions it aimed to answer was:

Do NfL, BLBP, and APP increase following exercise? Researchers compared the accumulation of NfL, BLBP, and NfL among runners, cyclists, rugby players, controls, and between sexes in each category.

Participants were asked to either run, bike, play a rugby match, or abstain from exercise. In the exercising group, blood was drawn from a vein prior to the activity, immediately after the activity, 30 minutes after the activity, 1 hour after the activity, 24 hours after the activity, 48 hours after the activity, and 72 hours after the activity. In the non-exercising group blood was drawn from a vein one time.

Conditions

  • Healthy Male and Female Subjects

Interventions

OTHER

Running

Participants were expected to run 6.44 kilometers.

OTHER

Cycling

Participants were expected to cycle 39 kilometers

OTHER

Rugby

Participants were expected to play in one rugby match.

OTHER

control group

Participants were asked to refrain from exercise for 24 hours.

Sponsors & Collaborators

  • Appalachian State University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-16
Primary Completion
2022-02-15
Completion
2022-02-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06804291 on ClinicalTrials.gov